Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area

PHASE3CompletedINTERVENTIONAL
Enrollment

516

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

May 31, 2013

Study Completion Date

August 31, 2013

Conditions
Moderate or Severe Submental Fullness
Interventions
DRUG

Deoxycholic acid injection

Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.

DRUG

Placebo

Phosphate buffered saline placebo for injection

Trial Locations (35)

10022

Investigational Site, New York

10065

Investigational Site, New York

10604

Investigational Site, White Plains

21093

Investigational Site, Lutherville

22911

Investigational Site, Charlottesville

27262

Investigational Site, High Point

28207

Investigational Site, Charlotte

32204

Investigational Site, Jacksonville

33146

Investigational Site, Coral Gables

45255

Investigational Site, Cincinnatti

46032

Investigational Site, Carmel

46617

Investigational Site, South Bend

48038

Investigational Site, Clinton Township

55424

Investigational Site, Edina

60563

Investigational Site, Naperville

60611

Investigational Site, Chicago

63141

Investigational Site, St Louis

72116

Investigational Site, Little Rock

75093

Investigational Site, Plano

78229

Investigational Site, San Antonio

78759

Investigational Site, Austin

80113

Investigational Site, Englewood

84117

Investigational Site, Salt Lake City

90067

Investigational Site, Los Angeles

90210

Investigational Site, Beverly Hills

90404

Investigational Site, Santa Monica

94115

Investigational Site, San Francisco

95817

Investigational Site, Sacramento

97035

Investigational Site, Portland

07042

Investigational Site, Montclair

T3G0B4

Investigational Site, Calgary

V3R 6A7

Investigational Site, Surrey

V5Z 4E1

Investigational Site, Vancouver

Unknown

Investigational Site, Oakville

L4L 8E2

Investigational Site, Woodbridge

Sponsors
All Listed Sponsors
lead

Kythera Biopharmaceuticals

INDUSTRY